High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors. (Q54132013)

25 May 2018

review article

1 reference

title

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors. (English)

1 reference

25 May 2018

author name string

W P McGuire

series ordinal

1

1 reference

25 May 2018

publication date

1 May 1998

1 reference

25 May 2018

Current Problems in Cancer

published in

1 reference

25 May 2018

volume

22

1 reference

25 May 2018

issue

3

1 reference

25 May 2018

page(s)

135-177

1 reference

25 May 2018

The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe?

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survi

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Window of opportunity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Adjuvant therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Dose-intensity in ovarian carcinoma: hold, enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

How many more nails to seal the coffin of dose intensity?

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Meta-analysis comparing cisplatin total dose intensity and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Long-Term Outcome of Patients with Relapsed and Refractory Germ Cell Tumors Treated with High-Dose Chemotherapy and Autologous Bone Marrow Rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

Phase II Trial of High-Dose Carboplatin and Etoposide With Autologous Bone Marrow Transplantation in First-Line Therapy for Patients With Poor-Risk Germ Cell Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2898%2990005-8

7 January 2021

10.1016/S0147-0272(98)90005-8

Identifiers

DOI

1 reference

25 May 2018

1 reference

25 May 2018